Michael Tobias Stumpp

USPTO Granted Patents = 15 (Patent Applications = 2)

CIPO Patents = 3

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 4.2

ph-index = 7

Forward Citations = 170(Granted Patents)

Location History:

Zürich, CH (2008 - 2014)
Zurich, CH (2016)
Geroldswill, CH (2016)
Geroldswil, CH (2012 - 2022)

Company Filing History:

7 out of 22

Molecular Partners Ag

Years Active: 2008-2022

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11332501 - Recombinant binding proteins and their use (2022-05-17),

2. 10646542 - Modified binding proteins inhibiting the VEGF-A receptor interaction (2020-05-12),

3. 10155791 - Recombinant binding proteins and their use (2018-12-18),

4. 9849158 - Modified binding proteins inhibiting the VEGF-A receptor interaction (2017-12-26),

5. 9657287 - Repeat protein from collection of repeat proteins comprising repeat modules (2017-05-23),

6. 9458211 - Recombinant proteins that simultaneously bind HGF, VEGF-A and serum albumin, comprising ankyrin repeat domains (2016-10-04),

7. 9447142 - Phage display using contranslational translocation of fusion polypeptides (2016-09-20),

8. 9365629 - Designed armadillo repeat proteins (2016-06-14),

9. 9289466 - Modified binding proteins inhibiting the VEGF-A receptor interaction (2016-03-22),

10. 9006389 - Repeat protein from collection of repeat proteins comprising repeat modules (2015-04-14),

11. 8901076 - Binding proteins inhibiting the VEGF-A receptor interaction (2014-12-02),

12. 8846577 - Phage display using cotranslational translocation of fusion polypeptides (2014-09-30),

13. 8710187 - Modified binding proteins inhibiting the VEGF-A receptor interaction (2014-04-29),

14. 8110653 - Collections of repeat proteins comprising repeat modules (2012-02-07),

15. 7417130 - Collection of repeat proteins comprising repeat modules (2008-08-26),

Title: An Overview of Inventor Michael Tobias Stumpp

Introduction

Michael Tobias Stumpp, a notable inventor based in Geroldswil, Switzerland, has made significant contributions to the field of biotechnology. With a remarkable portfolio of 15 patents, his work primarily focuses on the development of innovative binding proteins with therapeutic applications.

Latest Patents

Stumpp's latest patents include groundbreaking inventions related to recombinant binding proteins. One of his notable patents describes new designed ankyrin repeat domains that exhibit binding specificity for serum albumin. This invention highlights various designs of recombinant binding proteins, including those comprising multiple designed ankyrin repeat domains targeting hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF-A). These novel proteins, along with the nucleic acids encoding them, have potential applications in treating various diseases. Another significant patent focuses on modified binding proteins that inhibit the interaction of VEGF-A with its receptor, VEGFR-2. These recombinant binding proteins, which incorporate a polyethylene glycol moiety, show promise in treating cancer and ocular diseases, such as age-related macular degeneration.

Career Highlights

Throughout his career, Michael Tobias Stumpp has been affiliated with prominent institutions, including Molecular Partners AG and the University of Zurich. His innovative research and development efforts have positioned him as a leader in the biotechnology sector. His expertise in designing binding proteins has opened new avenues for therapeutic interventions in various medical conditions.

Collaborations

Stumpp has worked alongside notable colleagues, including Patrik Forrer and Hans Kaspar Binz. Their collaborative efforts have significantly advanced the research and application of binding proteins, enhancing the potential for impactful treatments in medicine.

Conclusion

Michael Tobias Stumpp's contributions to the field of biotechnology through his innovative patents and collaborations showcase the importance of research in developing therapeutic solutions. His work not only advances scientific understanding but also holds the potential to improve treatment options for patients suffering from various diseases, solidifying his role as a key figure in modern biotechnology.

This text is generated by artificial intelligence and may not be accurate.